DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lgbgww/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

• AbbVie
• Actinium
• Agios
• Altor BioScience
• Ambit Biosciences
• Amgen
• Astellas Pharma
• Astex
• AstraZeneca
• AVEO
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Conkwest
• Cornerstone
• CTI BioPharma
• Eisai
• EpiZyme
• Exelixis
• F. Hoffmann-La Roche
• Fujifilm Corporation
• Genoscience Pharma
• GlaxoSmithKline
• Igenica Biotherapeutics
• Incyte
• Jiangsu Hansoh Pharmaceutical
• JW Pharmaceutical
• Karyopharm Therapeutics
• Kyowa Hakko Kirin Co., Ltd.
• Les Laboratoires Servier SAS
• MacroGenics, Inc.
• Merck & Co., Inc.
• Millennium Pharmaceuticals, Inc.
• Novartis AG
• Piramal Enterprises Limited
• Plexxikon Inc.
• Polaris Group
• Seattle Genetics, Inc.
• Sunesis Pharmaceuticals, Inc.
• Synta Pharmaceuticals Corp.
• Targa Therapeutics Corp.
• Tolero Pharmaceuticals, Inc.
• Verastem, Inc.

For more information visit http://www.researchandmarkets.com/research/lgbgww/relapsed_acute